"A rose by any other name": does defining extreme phenotypes add to the management of multiple sclerosis?

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system characterized by recurrent episodes of neurological dysfunction. Diagnostic criteria have evolved over time but the core principles of “dissemination in time” and “dissemination in space” have been retained. Different clinical phenotypes are recognized, such as the commonly encountered relapsing remitting and secondary progressive forms of the disease. Less commonly patients may present with a progressive course from onset.

[1]  S. Viswanathan,et al.  Pure spinal multiple sclerosis: A possible novel entity within the multiple sclerosis disease spectrum , 2019, Multiple sclerosis.

[2]  David H. Miller,et al.  Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.

[3]  Jacqueline Palace,et al.  Clinical presentation and prognosis in MOG-antibody disease: a UK study , 2017, Brain : a journal of neurology.

[4]  B. Weinshenker,et al.  Progressive solitary sclerosis , 2016, Neurology.

[5]  A. Traboulsee,et al.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2015, Neurology.

[6]  A. Traboulsee,et al.  Treatment of Neuromyelitis Optica: Review and Recommendations. , 2012, Multiple sclerosis and related disorders.

[7]  F. Paul,et al.  Failure of natalizumab to prevent relapses in neuromyelitis optica. , 2012, Archives of neurology.

[8]  B. Kim,et al.  Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder , 2012, Multiple sclerosis.

[9]  D. Goodin,et al.  Establishing Long-Term Efficacy in Chronic Disease: Use of Recursive Partitioning and Propensity Score Adjustment to Estimate Outcome in MS , 2011, PloS one.

[10]  F. Moore.  INCIDENTAL MRI ANOMALIES SUGGESTIVE OF MULTIPLE SCLEROSIS: THE RADIOLOGICALLY ISOLATED SYNDROME , 2009, Neurology.

[11]  J. Parisi,et al.  Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. , 2007, Brain : a journal of neurology.

[12]  P. Vermersch,et al.  Immunosuppressive therapy is more effective than interferon in neuromyelitis optica , 2007, Multiple sclerosis.

[13]  Ichiro Nakashima,et al.  A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis , 2004, The Lancet.